

119TH CONGRESS
1ST SESSION

H. R. 1672

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 27, 2025

Mr. DAVIS of North Carolina (for himself, Mr. JOYCE of Pennsylvania, Mr. GOTTHEIMER, Ms. TENNEY, Mr. YAKYM, Mr. MORELLE, Mr. HUDSON, Mr. BEAN of Florida, Mrs. MILLER-MEEKS, Mr. ALLEN, Ms. VAN DUYN, Mr. PETERS, Mr. MOORE of Utah, and Mr. CRENSHAW) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Maintaining Invest-
5 ments in New Innovation Act”.

1 **SEC. 2. AMENDMENT TO DEFINITION OF QUALIFYING SIN-**
2 **GLE SOURCE DRUG.**

3 Section 1192(e) of the Social Security Act (42 U.S.C.
4 1320f–1(e)) is amended—

5 (1) in paragraph (1)(A)(ii), by inserting “(or,
6 in the case of an advanced drug product (as defined
7 in paragraph (4)), 11 years)” after “7 years”; and

8 (2) by adding at the end the following new
9 paragraph:

10 “(4) **ADVANCED DRUG PRODUCT DEFINED.**—
11 For purposes of paragraph (1)(A)(ii), the term ‘ad-
12 vanced drug product’ means a drug that incor-
13 porates or utilizes a genetically targeted technology
14 (as defined in section 529A(c)(2) of the Federal
15 Food, Drug, and Cosmetic Act) that may result in
16 the modulation (including suppression, up-regula-
17 tion, or activation) of the function of a gene or its
18 associated gene product.”.

○